Engineered Viruses Make Neurons Glow and Treat Brain Disease
The brain is like an ecosystem—thousands of different types of cells connect to form one big, interdependent web. And just as biologists document species of plants and animals, neuroscientists have spent decades identifying different 'species' of neurons and other brain cells that support them. They've found more than 3,000 cell types spread throughout the brain, including chandelier neurons surrounded by branching arms, pyramidal neurons with far-reaching nerve fibers and star-shaped astrocytes that help neurons form new connections with one another.
This newfound diversity is not only a beautiful picture for neuroscientists—it's also key to understanding how the brain works and what goes wrong in certain brain diseases. From Parkinson's disease to schizophrenia, many brain disorders stem from specific types of brain cells.
'As long as I've been doing neuroscience, it's been a goal of researchers to have brain-cell-type-targeting tools,' says Jonathan Ting of the Allen Institute, a nonprofit research center in Seattle. Now they have them in spades. In a fleet of eight studies funded by the National Institutes of Health and published last week, scientists from 29 research institutions found and tested more than 1,000 new ways to home in on specific cell types, no matter where they are in the brain.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
The technique behind these tools uses non-disease-causing viruses (called adeno-associated viruses, or AAVs) to deliver genes directly to specific neurons. This can make the cells do almost anything. Scientists can turn them off, activate them, 'light them up like a Christmas tree' with glowing proteins or deliver gene therapies right to them, says Ting, senior author of one of the new studies. The researchers have tested the technique only in nonhuman animals, but the bulk of the tools work across mammal species and would likely work in humans, too. Similar, less-targeted AAV gene therapies are already approved for treating spinal muscular atrophy and are being tested in clinical trials for Huntington's disease.
'There are a lot of good examples' of how AAVs are being used to treat brain disease, says Nikolaus McFarland, a neurologist at the University of Florida, who treats neurodegenerative diseases such as Parkinson's and Huntington's. 'It's really exciting stuff.'
Viral Shuttles
Every type of brain cell is like a unique creature. Scientists have categorized the cells based on their shape, location and electrical properties—and, more generally, based on the genes they express most out of an organism's full library of DNA. By expressing certain genes, these cells carry out specific actions, such as building specialized proteins. If researchers can identify a unique snippet of genetic code that is activated just in those cells, they can use that snippet to target them.
Next, they attach this genetic snippet, called an enhancer, to an AAV that has been gutted of its viral DNA. They can fill the viral husk with specific genes to deliver to those cells. The now-filled husks enter the bloodstream like a fleet of delivery shuttles, bypassing the blood-brain barrier, but are only able to activate their genetic cargo in cells with the enhancer.
In the new studies, researchers focused on cell types in three parts of the brain: the outer layer of brain tissue called the cortex that plays a role in higher-level thinking, the striatum, which is part of the basal ganglia (a stretch of deep brain tissue) that is impacted in Huntington's and Parkinson's disease, and the spinal cord, whose motor neurons are destroyed in amyotrophic lateral sclerosis (ALS). The consortium of 247 scientists was funded by the NIH's Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative as a part of a larger research project called the Armamentarium for Precision Brain Cell Access. The scientists found and tested more than 1,000 enhancer AAVs, now freely available to researchers, that target specific cell types in those key brain regions.
Tweaking the Brain
Previously, these enhancer AAVs had been developed in a slow trickle by different labs, but 'now we have thousands of tools' to tweak specific cell types, says Bosiljka Tasic, director of molecular genetics at the Allen Institute and senior author of one of the new studies.
Researchers can load these AAV shuttles with all sorts of different genes to answer different questions. In some cases, even just seeing the neurons in action is cause for celebration: 'Some of them are very rare cells that you wouldn't find randomly by poking around in brain tissue,' Ting says. To observe them, researchers can introduce a gene that makes a glowing protein that lights up elusive neurons from the inside to reveal their structure and how they connect with other brain cells.
Researchers can also control how certain brain cells fire and turn their activity up or down to see how the change impacts an animal's behavior. To do this, researchers insert a gene into the target cells that creates a light-sensitive protein called an opsin; then they can shine specific wavelengths of light on the brain to make those cells fire on command. Ting's team used this technique, called optogenetics, to stimulate certain cells in the striatum of mice. When the researchers stimulated those cells on just one side of the brain, the mice began moving more on one side of their body than the other, causing them to go in circles.
These interventions are reversible and repeatable. 'That's the part that's really satisfying for neuroscientists,' Ting says. 'You can turn them off, turn them back on and then see how that affects the brain circuit.'
It's ' so much better and also so much more informative' than destroying whole parts of a mouse brain to see what happens, as is the case with much neuroscience research from the past century, Tasic says. 'That brain region may have a hundred different cell types,' so being able to activate and inactivate them more precisely will reveal more information about how these circuits work, she says.
New Treatments
So far, the new enhancer AAVs have been tested in mice, rats and macaques. 'We keep trying more and more species,' Ting says. 'We haven't even figured out what's the limit.'
And that brings us to humans. 'That's really the answer to the question 'Why do we care?'' he says. 'We have built strong evidence that some of these tools—maybe not all of them, but many of them—may work across species into humans and could represent the start of a new therapeutic vector development that could be used to more finely treat debilitating brain disorders.'
For these treatments, enhancer AAVs could deliver gene therapy right to the brain cells that need it. The best candidates for this technique are neurodegenerative diseases, such as ALS, Parkinson's disease and Huntington's disease. Researchers are currently working on AAV gene therapies for these conditions and others that target whole regions of the brain rather than specific types of brain cells. Trials of these therapies indicate that they are largely safe. 'We now have lots of good examples of AAV being used,' McFarland says. 'We have [a] good safety record for that.'
'There's a lot that we still don't understand about neurodegenerative diseases,' he adds, and these little viral shuttles will allow scientists to make those discoveries that enable new treatments. While each of these brain disorders is unique, cracking one of them might help scientists crack the others, too, McFarland says: 'I wholeheartedly believe that.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
11 hours ago
- Axios
Vanderbilt University Medical Center announces up to 650 layoffs
Vanderbilt University Medical Center announced Friday that up to 650 people would be laid off as the institution scrambles to respond to the Trump administration's steep cuts to medical research. The big picture: The Trump administration is pursuing massive cuts to National Institutes of Health research grants and to the Department of Health and Human Services. The budget bill pending in Congress proposes deep cuts to Medicaid, which provides health insurance to 83 million low-income adults and their children. Aggressive cuts have put research hospitals across the country on their heels. VUMC president and CEO Jeff Balser previously warned that the federal cuts would lead to layoffs and hobbled research projects. Flashback: In March, VUMC announced plans to slash its budget by $250 million because of the Trump administration's spending cuts. At the time, Balser said more cuts and layoffs could be needed as the scope of the funding fallout became clear. The latest: In a new statement Friday, VUMC said operating costs would be cut by $300 million due to "budgetary actions in Washington, DC related to government-sponsored research and patient care." Layoffs will hit up to 650 employees "primarily in research, administrative and other support areas." That total includes employees who were already laid off earlier this year as well as a new round of reductions that began Friday. VUMC announced staffing reductions in a video message to employees. What they're saying:"While this is extremely difficult, the staffing loss represents less than 2% of VUMC's total workforce," the VUMC statement read. Laid off employees will get severance and "other assistance." "VUMC sees more than 3.5 million patient visits each year and remains committed to meeting the needs of all who depend on us for health care."
Yahoo
a day ago
- Yahoo
MOTE Marine Laboratory heads up seagrass initiative as other scientists call for water quality improvements
The Brief MOTE Marine Laboratory heads seagrass restoration technology development initiative. Funding comes from the Florida legislature after seagrass has declined across the state. Other scientists say more is needed, including storm and wastewater improvements. SARASOTA, Fla. - Seagrass plays a vital part in not only protecting Florida shorelines from erosion, but it also helps the underwater ecosystem thrive. In recent years, there has been a loss of seagrass across the state. The backstory Mote Marine Laboratory in Sarasota is trying to figure out how to stop this from happening. Seagrass is a breeding ground and protector for game fish. It's also a source of food for manatees and can help improve water quality. In areas across the state of Florida, seagrasses are disappearing. OTHER NEWS: Shark bite survivor's family, TGH doctors discuss 9-year-old's recovery: 'She's done a fantastic job' "We've seen stressors all across the state of Florida impacting our seagrass beds, which are so vital for our water quality, nursery grounds," said Kevin Claridge. Kevin Claridge is Mote Marine Laboratory's Vice President of Sponsored Research and Coastal Policy Program. He said Mote Marine Laboratory is working with the Florida Department of Environmental Protection and the University of Florida in creating a 10-year Florida seagrass restoration plan. Big picture view "Specifically, the funding is looking at what those stressors are on those seagrass systems. Say it's nutrient change or acidification or less light or nutrient impacts," said Claridge. The Florida Legislature has approved $2 million dollars in funding to be awarded every year for 5 years for the Seagrass Restoration Technology Development Initiative. The hope is to find the most tolerant seagrasses that Mote Marine Laboratory and partners can grow for future restoration projects. "It's the first time ever really on an international scale. We are working with partners all over the world and what they are doing in planting technologies to understand that genetic makeup better, to help us understand which ones are growing faster," said Claridge. Sarasota Bay has seen big gains. In 2024, they witnessed a 19% increase in seagrass coverage. Dr. David Tomasko, the Director of the Sarasota Bay Estuary Program, said it happened after local governments worked on removing nutrients from the water. "None of that 2,000 acres came about by transplanting. It came about because the water quality improved because we spent $300 million improving water quality," he said. Tomako said while the science of growing seagrass is vital, additional funds allocated to wastewater upgrades and storm water retrofits should be considered. "We want both these things to happen. We want the science to move forward, but we also don't want elected officials in Tallahassee or Washington D.C. to take their eye off the ball, which is we can recover eco-system scale, but it will cost more than 10-20 million dollars," he said. He said without change, sea grass will continue to pay the price as Florida grows. "If you're not willing to, at the same time, devote enough resources for these big projects. Wastewater upgrades, storm water retrofits it doesn't understand how well you understand the seagrasses. They won't grow if the water quality is not good," said Tomasko. What's next Mote Marine Laboratory has completed a green house which will help them experiment on real world stressors to sea grass. They hope to identify seagrass types which are most resilient to outside changes. Scientists are also looking at genetic and genomic approaches to generate genetically resilient seagrass which could be natural reproduced in land-based nurseries. The Source: Information was gathered by FOX 13's Kimberly Kuizon from Mote Marine Laboratory and the Sarasota Bay Estuary Program. The Source FOX 13's Kimberly Kuizon gathered the information for this story. STAY CONNECTED WITH FOX 13 TAMPA: Download the FOX Local app for your smart TV Download FOX Local mobile app: Apple | Android Download the FOX 13 News app for breaking news alerts, latest headlines Download the SkyTower Radar app Sign up for FOX 13's daily newsletter Follow FOX 13 on YouTube
Business Wire
2 days ago
- Business Wire
Clinical Milestones, Vector Innovation Key to Gene Therapy, GenoTher Biocluster's First International Summit,
PARIS--(BUSINESS WIRE)--Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), and its spin-off Atamyo Therapeutics made significant advances in their gene therapies for multiple rare diseases as highlighted in Genethon's most recent Newsletter. Chief among them are key clinical milestones reached, including those reflected in Genethon's Phase 3 ready Duchene muscular dystrophy gene therapy (GNT0004); and Atamyo's significant milestones in clinical trials of gene therapies (ATA-100 and ATA-200) for treatment of two subtypes of limb-girdle muscular dystrophy (LGMD2I/R9 and LGMD2C/R5). In addition, the GenoTher Biocluster, a public-private partnership serving as a leading ecosystem for generation of innovative genetic medicines' approaches, held its first international summit attended by 350 researchers, investors, biotech executives and public decision-makers representing more than 100 organizations. In his CEO Commentary, Genethon's Frederic Revah discusses new research involving the organization's AAV platform to increase safety, efficacy and disease applications of gene therapies. Dr. Revah reports Genethon also is exploring non-viral based delivery systems, such as Lipid Nano Particles (LNPs), for their potential in gene editing. Atamyo in April completed the dose escalation phase of a Phase 1b/2b trial in Europe of ATA-100 for LGMD2I/R9 and announced in June dosing in the US of the first two patients in a Phase 1b/2 study of ATA-200 for LGMD2C/R5. Both subtypes lead to loss of ambulation and other complications in children and there are no cures. Read the full Newsletter to learn about these gene therapy advances and others. About Genethon As a pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a non-profit laboratory that was established by AFM-Telethon. A first gene therapy for spinal muscular atrophy to which Genethon contributed has obtained a product license. With more than 200 scientists and professional staff, Genethon is pursuing its aim to develop therapies which change the lives of patients suffering from rare genetic diseases. Thirteen products stemming from Genethon's R&D or from collaborations are in clinical trial for diseases of the liver, blood, immune system, muscles and eyes. Seven other products could enter clinical trials over the next five years. More information at
